The term “Ozempic personality” has emerged online and among some patients to describe emotional flattening, reduced motivation, or a loss of pleasure while taking GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound.
The Washington Post examined the phenomenon in a report published Thursday, April 16, noting that doctors and patients have described a dulled response not only to food, but also to hobbies, socializing, music, exercise, and romance.
The term is not an official diagnosis. Experts say the science is still developing, and it remains unclear whether the reported changes are caused by the drugs, weight loss itself, shifting habits, or some combination of factors.
GLP-1 medications mimic hormones involved in appetite and blood sugar regulation. They also interact with brain pathways tied to reward, motivation, and pleasure, according to The Washington Post.
That may help explain why many patients report less “food noise,” or fewer persistent thoughts about eating. But some patients say the same quieting effect can leave other parts of life feeling muted.
Reports of emotional flattening do not appear to be widespread, doctors told The Post. Many patients instead report better mood, more energy, and improved confidence after weight loss.
A 2024 case report published in “Innovations In Clinical Neuroscience” and indexed by the National Library of Medicine described worsened depression in a patient taking semaglutide, the active ingredient in Ozempic and Wegovy. Case reports can raise questions, but they do not prove cause and effect.
The Washington Post also cited research suggesting semaglutide may be linked to lower risks of worsening depression, anxiety, substance use disorder, and self-harm among some patients with diabetes or obesity and existing mental health conditions.
That mixed picture is why experts say patients should not stop taking prescribed medication on their own.
Click here
to follow Daily Voice
Lower Merion-Narberth
and receive free news updates.